Mariel Therapeutics, Inc. acquired Ember Therapeutics, Inc. from Third Rock Ventures II, L.P. of Third Rock Ventures II, L.P. for $6 million on March 11, 2015. Under the terms of the agreement, Third Rock Ventures II, L.P will receive $2 million of 8% convertible notes for all preferred stock plus the right to receive certain contingent consideration of maximum of $4 million if any shares of Ember are listed for trading on a securities exchange and, for a period of 30 consecutive calendar days, the average closing market capitalization equals or exceeds $300 million, an amount in cash equal to $2 million payable within five business days after the first to occur of (A) a buyer change of control or (B) buyer's entry into a license or commencement of a phase 2 clinical trial, in either case related to a product candidate with an indication related to metabolic disease and each of common stock was cancelled before the effective time and retired without payment of any consideration therefore. The combined entity shall be named as Ember Therapeutics, Inc.

Mariel Therapeutics, Inc. completed the acquisition of Ember Therapeutics, Inc. from Third Rock Ventures II, L.P. of Third Rock Ventures II, L.P. and others on March 11, 2015.